'This is a culmination of many years' work by our group and we look forward to working with PharmaCyte's Diabetes Consortium to utilise the Cell-in–a-Box technology to encapsulate the cells for preclinical trials aimed at curing diabetes,' said Professor Simpson.
辛普森教授说道,“这是我们团队多年努力研究的结果,我们期待与PharmaCyte公司的糖尿病团队合作,在治疗糖尿病的临床前试验中利用Cell-in–a-Box技术将细胞胶囊化。”
'We anticipate that the capsule technology will protect the Melligen cells from the body's immune response that normally destroys foreign tissue, allowing the Melligen cells to be transplanted into humans.'
“我们预计胶囊技术能保护Melligen细胞不被人体免疫系统当成外来组织破坏掉,以便顺利植入人体。”
PharmaCyte's chief executive officer, Kenneth Waggoner, said: 'We at PharmaCyte consider ourselves to be very fortunate in having secured the exclusive world-wide licence to use the Melligen cells to develop a treatment for diabetes.
PharmaCyte首席执行官肯尼思•瓦戈纳说道,“PharmaCyte有幸获得全球独家许可,运用Melligen细胞研发糖尿病疗法,真的非常幸运。”
'For the millions of people worldwide who suffer from a disease of epidemic proportions, our treatment could relieve them of the onerous daily requirements for insulin administration and dietary restrictions and offer a life free from the very serious and even life-threatening complications associated with diabetes.'
【澳洲新基因改良技术:不打胰岛素也能治糖尿病】相关文章:
★ 用白菜制作的美女
★ “大白兔冰淇淋”在美火爆,奶糖原料被抢光,冠生园:没授权啊
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15